• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOCOMPATIBLES UK LTD THERASPHERE YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOCOMPATIBLES UK LTD THERASPHERE YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW Back to Search Results
Model Number 5.14 GBQ
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Death (1802); Diarrhea (1811); Encephalopathy (1833); Fatigue (1849); Hyperbilirubinemia (1903); Liver Damage/Dysfunction (1954); Ascites (2596); Weight Changes (2607); Test Result (2695)
Event Date 03/01/2019
Event Type  Death  
Manufacturer Narrative
Btg medical assessment: patient received a treatment with therasphere®, quite a high activity to the right liver, in a patient for whom, at baseline, there was a warning regarding the administration of therasphere®, (bilirubin >34 micromol/l), therefore this patient was at high risk of complication. Due to the poor baseline liver function the treatment lead to deterioration of the pre-existing altered liver function with the occurrence within one month after treatment of ascites, encephalopathy, asthenia, degradation of ecog status, elevation of bilirubin, albumin decrease, weight loss, fatigue, elevation of creatinine, decrease of coagulation test. In conclusion: liver function degradation leading to death due to therasphere® administration and disease progression in a patient with pre-existing altered liver function. Ascites: severity 4; serious; related device; anticipated deterioration of ecog status: severity 2; non-serious; related device; anticipated weight loss/anorexia: severity unknown; non-serious; related device; anticipated liver function deterioration: severity 4; serious; related device and disease progression; anticipated. Confusion: severity unknown; non-serious; related to liver function deterioration; anticipated. Blood bilirubin increase: severity 2 (basline abnormal); non-serious; related to liver function deterioration; anticipated. Hypoalbuminemia: severity 2; non-serious; related to liver function deterioration; anticipated. Asthenia/fatigue: severity 3; non-serious; related to liver function deterioration; anticipated. Alt increase: severity 2; non-serious; related to liver function deterioration; anticipated ast increase: severity 3; non-serious; related to liver function deterioration; anticipated deterioration of coagulation test: severity 3; non-serious; related to liver function deterioration; anticipated. Diarrhoea: severity unknown; non-serious; related to liver function deterioration; anticipated. Coagulation test deterioration: severity 4; non-serious; related to liver function deterioration; anticipated creatinine increase: severity 2; non-serious; related to liver function deterioration; anticipated. Encephalopathy: severity 4; serious; related to liver function deterioration; anticipated death: severity 5; serious; related to liver function deterioration; anticipated. No device malfunction was reported and no corrective and preventive action (capa) plan has been identified. The lot number associated with the therasphere administration was not reported, therefore no investigation could be performed. If additional information becomes available, a follow up report will be submitted. No other information is available that could confirm/deny the alleged event. At this time this report is considered final.
 
Event Description
Auto-notification received from datatrak 13-feb-2020 for a patient enrolled on the (b)(6) study as follows: site number (siteid): (b)(4). Unique patient id: (b)(6). Sae number: 1 diagnostic term to describe primary sae: edemato-ascites decompensation. Seriousness criteria: led to a death. Start date: (b)(6) 2019. Sae outcome: fatal. Severity (ctcae v5. 0 grade): (saesev): grade 4. Causality related to administration procedure (saecausdev): probably. Causality related to therasphere device (saecausmaa): probably. Incident: on (b)(6) 2019 (1st occurrence of ascites) at the first follow-up visit post treatment the patient presented, grade 3 ascites, jaundice with bilirubin at 76 umol/l (grade 3), ecog 2. A paracentesis was performed (3l), ascites non infected: liver function deterioration post sir, with ascites on (b)(6) 2019 (2nd occurrence of ascites) the patient was hospitalised for paracentesis, evacuation of 4 l of ascites with no infection. Weight loss of -15kg within 18days - anorexia, no asthenia. On (b)(6) 2019 the patient was hospitalised - (unknown adverse event), no ascites subtraction, prothrombin ratio (pr) 31%, on (b)(6) 2019 asthenia, diarrhoea, confusion, prescription of lactulose. On (b)(6) 2019: pr 41% (grade 2). Albumin 23 g/l (grade 3), bilirubin 86 micromo/l (grade 3), ast 140ui/ll, child c10 and on a ct scan on (b)(6) 2019 confirmed liver progression in the left liver. On (b)(6) 2019 the patient was hospitalised again: pr13%. Alteration of liver function test on (b)(6) 2019 the patient was re admitted to the hospital, no ascites subtraction, confusion (encephalopathy), asthenia, albumin 24 g/l, bilirubin 266 micromol/l, renal insufficiency with creatinine 272 micromol/l; grade 3 encephalopathy, ascites, child >c10 and the patient died the (b)(6) 2019. Ast
=
320 (grade 3), alt
=
184 ui/l. The patient died the (b)(6) 2019. The investigator assessed the events as follows: ascite :serious. Probably related to administration and the therasphere device therasphere treatment: patient received one administration of therasphere the (b)(6) 2019, 5. 14 gbq in the right hepatic artery.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameTHERASPHERE
Type of DeviceYTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW
Manufacturer (Section D)
BIOCOMPATIBLES UK LTD
chapman house farnham bus park
weydon lane
farnham, GU9 8 QL
UK GU9 8QL
Manufacturer (Section G)
BIOCOMPATIBLES UK
chapman house
weydon lane
farnham, GU9 8 QL
UK GU9 8QL
Manufacturer Contact
sandra bausback-aballo
300 four falls corporate cente
300 conshohocken state road
west conshohocken,, pa 
3311537
MDR Report Key9811688
MDR Text Key182801887
Report Number3002124543-2020-00002
Device Sequence Number1
Product Code NAW
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
H980006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,s
Reporter Occupation
Type of Report Initial
Report Date 02/13/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/10/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Device Model Number5.14 GBQ
Device Catalogue NumberN/A
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received02/13/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 03/10/2020 Patient Sequence Number: 1
-
-